HK Stock Market Move | MEDCAPTAIN (02041) rose nearly 3% in morning trading; Morgan Stanley initiates coverage with an "Overweight" rating, bullish on the value of the company's platform-based business model.

MEDCAPTAIN (02041) rose nearly 3% in morning trading, up 1.59% as of press time at HK$6.4. Morgan Stanley recently issued a research report, initiating coverage on MEDCAPTAIN with an "Overweight" rating and a target price of HK$11. The report stated that MEDCAPTAIN holds leading positions in multiple product segments, continues to expand its global business footprint, and has a proven track record in M&A integration. Morgan Stanley is bullish on the value of the company's platform-based business model. Morgan Stanley noted in the report that MEDCAPTAIN has completed product lines in anesthesia, airway management, and minimally invasive intervention through the acquisitions of Penlon and Weidekang, and can leverage its platform advantages to build cross-department solutions and unlock diversified synergistic sales potential. Combined with the long-term prosperity of domestic life support, minimally invasive intervention, and IVD sectors, Morgan Stanley is bullish on the company's product iteration and global expansion momentum.